Literature DB >> 6541293

Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.

V C Jordan, M E Lieberman.   

Abstract

An in vitro assay that depends upon the synthesis of prolactin by primary cultures of dispersed cells from immature rat pituitary cells was used to study the structural requirement for estrogen action. Two categories of estrogens were identified: full estrogens (agonists) and partial estrogens (partial agonists) with antiestrogenic actions against the effects of 0.1 nM estradiol (E2). All of the agonists [diethylstilbestrol (DES), dimethylstilbestrol (DMS), R2858, and RU16117] produced a dose-related increase in prolactin synthesis equivalent to E2, although potencies were different: E2 = DES = R2858 greater than RU16117 greater than DMS. Partial agonists [ICI 3188, tri(4-hydroxyphenyl)chloroethylene, and bisphenol] each had bis(4-hydroxyphenol) substitutions at the ethylene double bond and stimulated prolactin synthesis only to about 50% of the maximal response observed with E2. Trianisylchloroethylene was weakly active as a partial agonist, but at high concentration (10 microM) was able to decrease prolactin synthesis produced by 0.1 nM E2. Previous studies from these laboratories showed that triphenylethylene derivatives with a strategically located alkyl aminoethoxyside chain are complete E2 antagonists with no agonist activity. Two series of novel compounds were assayed to determine whether their structures would predict biological activity. LN2299, the cis geometric isomer of a triphenylbromethylene, was a full agonist with activity equivalent to zuclomiphene, the cis geometric isomer of clomiphene. Cyclofenyl was a partial agonist, but deacetylation to the diphenol increased partial agonist activity and potency. However, introduction of a single pyrrolidinoethylside chain into the deacetylated cyclofenyl increased antiestrogenic potency and completely suppressed the expression of agonist activity. Finally, LN2833, with a novel C(OH)CH3 side chain in the position normally occupied by the alkylaminoethoxyside chain of most antiestrogens, produced antiestrogen activity with no estrogen properties. Antiestrogenic potency was increased in LN2839 by a phenol in the triphenylethylene in a position equivalent to the 3-phenolic hydroxyl of E2. In general, the potency and biological properties could be predicted by reference to the structure of the molecule. Potent estrogens or antiestrogens have a phenolic hydroxyl in a position that would be equivalent to the 3-phenolic hydroxyl of E2. Partial agonist action is predicted by a 4-hydroxyphenol attached to the same carbon as the phenyl ring equivalent to the A-ring of E2.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541293

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

2.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

3.  Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro.

Authors:  V C Jordan; R Koch; S Mittal; M R Schneider
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

Review 4.  Membrane oestrogen receptors on rat pituitary tumour cells: immuno-identification and responses to oestradiol and xenoestrogens.

Authors:  C S Watson; C H Campbell; B Gametchu
Journal:  Exp Physiol       Date:  1999-11       Impact factor: 2.969

5.  The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.

Authors:  V Craig Jordan
Journal:  Ann Surg Oncol       Date:  2019-03-25       Impact factor: 5.344

6.  Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures.

Authors:  Balkees Abderrahman; V Craig Jordan
Journal:  Cancer J       Date:  2022 May-Jun 01       Impact factor: 2.074

7.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

Authors:  S Sengupta; I Obiorah; P Y Maximov; R Curpan; V C Jordan
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Acetoxy substituted 1,1,2-triphenylbut-1-enes: estrogenic, antiestrogenic and mammary tumor inhibiting activity.

Authors:  M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 10.  Molecular mechanisms of antiestrogen action in breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.